Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 6.08B 5.33B 4.92B 4.6B 8.63B 574B 8.81B 59.1B 22.87B 284B 22.85B 22.35B 984B P/E 2026 *
70.1x
P/E 2027 * 37x
Enterprise Value 6.08B 5.33B 4.92B 4.6B 8.63B 574B 8.81B 59.1B 22.87B 284B 22.85B 22.35B 984B EV / Sales 2026 *
21.2x
EV / Sales 2027 * 16.4x
Free-Float
97.62%
Yield 2026 *
-
Yield 2027 * -
1 day+2.59%
1 week+10.44%
Current month+30.88%
1 month+29.37%
3 months+55.30%
6 months+55.03%
Current year+60.57%
1 week 258
Extreme 258
305.71
1 month 222.76
Extreme 222.76
305.71
Current year 175.89
Extreme 175.89
305.71
1 year 111.72
Extreme 111.715
305.71
3 years 49.24
Extreme 49.24
305.71
5 years 49.24
Extreme 49.24
305.71
10 years 49.24
Extreme 49.24
305.71
Manager TitleAgeSince
Chief Executive Officer 66 05/12/2022
Director of Finance/CFO 47 21/05/2015
Director of Finance/CFO 56 01/11/2022
Director TitleAgeSince
Chairman 76 01/03/2003
Director/Board Member 58 27/09/2006
Director/Board Member 66 01/03/2007
Date Insider Type Main position Quantity % Market Cap.
06-16Fiscal year

Director

6,435 0.0321%
06-12Fiscal year

Director

14,461 0.0722%
06-11Sell

Director

-4,500 0.0225%
Change 5-day change 1-year change 3-year change Capi.($)
+2.59%+10.44%+165.96%+321.30% 6.08B
+7.13%+9.97%+55.80%+163.38% 1,077B
+3.99%+11.50%+67.09%+56.27% 613B
+4.20%+17.03%+38.97%+91.19% 448B
+0.64%+4.85%+28.17%+22.04% 332B
-0.31%+7.61%+41.32%+27.29% 293B
-0.21%+4.94%+31.25%+41.61% 286B
-1.32%+5.00%-28.36%-40.95% 215B
+1.56%+6.14%+29.30%+61.91% 193B
+3.26%+3.33%+15.55%+67.87% 159B
Average +0.09%+8.67%+44.50%+81.19% 362.22B
Weighted average by Cap. +0.03%+9.65%+42.00%+81.29%

Financials

2026 *2027 *
Net sales 288M 252M 232M 218M 408M 27.14B 417M 2.79B 1.08B 13.41B 1.08B 1.06B 46.5B 371M 325M 299M 280M 526M 34.96B 537M 3.6B 1.39B 17.28B 1.39B 1.36B 59.91B
Net income 92.7M 81.28M 74.92M 70.14M 132M 8.74B 134M 900M 348M 4.32B 348M 340M 14.99B 178M 156M 144M 135M 253M 16.81B 258M 1.73B 670M 8.31B 669M 654M 28.81B
Net Debt - -
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Employees
47
Date Price Change Volume
26/06/26 $303.59 +2.59% 1,250,980
25/06/26 $295.92 +3.86% 711,084
24/06/26 $284.91 +1.96% 548,917
23/06/26 $279.44 +6.59% 2,298,219
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
303.59USD
Average target price
277.60USD
Spread / Average Target
-8.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGND Stock